Larazotide Acetate

Mechanism

A peptide that tightens the junctions between cells in your gut lining, preventing "leaky gut." It blocks zonulin, a protein that opens these gaps. Originally developed for celiac disease, it's the first drug specifically targeting intestinal permeability. May help with various autoimmune and inflammatory gut conditions.

Effects

## Gastrointestinal/Barrier System [Tier 1 - Phase III Human Data] - Synthetic octapeptide that antagonizes zonulin, the endogenous regulator of intestinal tight junctions - Zonulin (pre-haptoglobin 2) opens tight junctions between enterocytes — larazotide blocks this, tightening the paracellular barrier - Reduces intestinal permeability as measured by lactulose/mannitol ratio in human trials - Phase IIb trial in celiac disease showed significant reduction in symptoms and gluten-induced intestinal permeability - Phase III (CeDLara) trial completed for celiac disease — results mixed on primary endpoint but showed symptom improvement in subgroups ## Immune System [Tier 2 - Human Data] - By reducing paracellular permeability, larazotide decreases antigenic traffic across the intestinal barrier - In celiac disease: reduced gliadin peptide translocation triggers less T-cell activation and less inflammatory cascade - Theoretical benefit in any condition where intestinal permeability drives immune activation: autoimmunity, food sensitivities, systemic inflammation - Does NOT suppress the immune system — it reduces the antigenic load that triggers inappropriate immune responses ## Systemic/Multi-Organ [Tier 2 - Mechanistic/Observational] - "Leaky gut" (increased intestinal permeability) has been implicated in: autoimmune diseases (type 1 diabetes, rheumatoid arthritis, MS), allergies, chronic fatigue, mood disorders, and metabolic syndrome - By tightening the intestinal barrier, larazotide theoretically reduces systemic endotoxin (LPS) exposure and chronic low-grade inflammation - Reduced circulating LPS could improve insulin sensitivity, hepatic inflammation, and neuroinflammation - These systemic benefits are mechanistically plausible but not yet demonstrated in controlled trials for non-celiac indications ## Gastrointestinal Symptoms [Tier 1 - Human Data] - Reduction in celiac disease symptoms: abdominal pain, bloating, diarrhea, nausea - CeD-PRO (celiac disease patient-reported outcome) scores improved significantly vs. placebo in Phase IIb - Effects observed even in patients on a gluten-free diet (addressing inadvertent gluten exposure)

Practitioner Guide

## Clinical Positioning Larazotide is the most scientifically validated approach to "leaky gut" — a concept that has been controversial in mainstream medicine but is increasingly recognized through the work of Dr. Alessio Fasano on the zonulin pathway. Larazotide directly targets the zonulin mechanism, making it the most specific intestinal permeability therapy available. ## Current Availability (as of early 2026) - Phase III trial for celiac disease completed (9 Meters Biopharma) - NOT yet FDA-approved - Available through select compounding pharmacies and research peptide suppliers - The celiac disease trials established dosing and safety, making off-label use relatively well-informed ## Dosing (From Clinical Trials) - 0.5mg oral, three times daily, 15 minutes before meals - Higher doses (1mg, 2mg TID) were tested but did NOT show superior efficacy — 0.5mg TID appears optimal - Must be taken BEFORE meals to be present in the gut lumen when food antigens arrive - Oral administration — larazotide acts locally in the gut lumen and is not systemically absorbed ## Who Benefits Most Ideal candidates: - Celiac disease patients on GF diet with persistent symptoms (inadvertent gluten exposure) - Diagnosed increased intestinal permeability (lactulose/mannitol test, zonulin levels) - Autoimmune conditions with suspected gut permeability component - Food sensitivities with GI and systemic symptoms - Patients with chronic gut inflammation unresponsive to standard approaches Less clear benefit: - Healthy individuals without permeability issues - Patients with structural GI disease (Crohn's strictures, etc.) ## Testing for Intestinal Permeability - Serum zonulin levels (elevated = increased permeability) — available through specialty labs - Lactulose/mannitol urine test — gold standard but cumbersome - Anti-zonulin antibodies and anti-actin antibodies (Cyrex Array 2) - Calprotectin (inflammation marker, not permeability per se) ## Stacking - BPC-157 + Larazotide: complementary — BPC-157 heals mucosal damage, larazotide seals tight junctions. This is the most logical gut-healing stack. - KPV + Larazotide: KPV reduces NF-kB driven inflammation, larazotide reduces antigenic trigger. Anti-inflammatory + barrier restoration. - BPC-157 + Larazotide + KPV: the "triple gut protocol" — heal (BPC), seal (larazotide), calm (KPV) - L-glutamine (5-10g/day): supports enterocyte metabolism and tight junction protein expression — synergistic with larazotide - Zinc carnosine: additional tight junction support and mucosal healing ## What to Tell Patients "Larazotide works by blocking the protein (zonulin) that opens the gaps between your gut cells. Think of it as tightening the seals between bricks in a wall — keeping food particles and bacteria on the inside of the gut where they belong, instead of leaking into your bloodstream where they trigger inflammation." ## Timeline - Week 1-2: some patients notice reduced bloating and GI discomfort - Week 2-4: symptom improvement becomes more consistent - Month 1-3: full benefit; intestinal permeability markers may normalize - Ongoing: continued use recommended for maintained benefit; effects are not permanent after discontinuation

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No adequate human safety data during pregnancy. While larazotide acts locally in the GI tract with minimal systemic absorption, the safety during pregnancy has not been established.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on safety during lactation. While minimal systemic absorption is expected, safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Mechanical GI obstruction
  Larazotide is an oral peptide that acts on intestinal tight junctions. Mechanical GI obstruction prevents normal transit and may lead to unpredictable drug accumulation.
  Action: Do not use in patients with known or suspected mechanical GI obstruction.
• hard stop — Under 18 years of age
  Investigational compound. Not for pediatric use outside clinical trials.
  Action: Do not provide to individuals under 18.

Evidence

• Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial

  Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, Rasmussen H, Wang C, Bercik P, Bachir NM, Murray JA (2015) — Gastroenterology — PMID: 25311786

  Larazotide acetate (tight junction regulator) 0.5 mg three times daily significantly reduced symptoms in celiac disease patients on a gluten-free diet who had persistent symptoms. The primary endpoint of symptom reduction was met at the lowest dose. Mechanism involves preventing tight junction opening and reducing intestinal permeability triggered by gluten peptides.

  strong

Stacks featuring this peptide

Research Summary

## Tier 1 — Human Clinical Trials - Phase IIb (CelProCel, n=342): larazotide 0.5mg TID significantly reduced celiac disease symptoms (CeD-PRO score) vs. placebo in patients on GF diet. Higher doses (1mg, 2mg) were not superior. - Phase III (CeDLara): completed for non-responsive celiac disease. Mixed results on primary endpoint; subgroup analyses showed benefit in symptomatic patients with documented permeability issues. - Lactulose/mannitol ratio: reduced by larazotide in multiple studies, confirming mechanism of action in humans. - Safety: excellent across all trials. No serious adverse events attributed to larazotide. Adverse event profile similar to placebo (it is not systemically absorbed). - Multiple Phase II studies confirmed dose-dependent reduction in intestinal permeability after gluten challenge. ## Tier 2 — Mechanistic Human Data - Zonulin pathway (Fasano et al.): gliadin and bacteria trigger zonulin release from enterocytes → zonulin binds PAR2 and EGFR on adjacent enterocytes → tight junction disassembly → increased paracellular permeability - Larazotide acts as a competitive antagonist at the zonulin receptor complex - Serum zonulin levels correlate with intestinal permeability and predict larazotide response - Biopsy data show restoration of tight junction protein expression (ZO-1, claudin, occludin) with larazotide treatment ## Tier 3 — Preclinical - Zonulin transgenic mice show increased permeability and autoimmune phenotype - Larazotide prevents gliadin-induced permeability increase in ex vivo intestinal preparations - Non-celiac applications (type 1 diabetes, IBD): promising animal data showing reduced disease severity with permeability normalization ## Evidence Gaps - FDA approval pending — regulatory path unclear after Phase III mixed results - Non-celiac applications (IBS, autoimmunity, metabolic syndrome) not studied in controlled human trials - Long-term (>1 year) safety and efficacy data limited - Biomarker-guided patient selection not validated - Combination with BPC-157 or other gut peptides never studied